证券之星消息，截至2026年1月9日收盘，稳健医疗(300888)报收于39.17元，上涨1.03%，换手率 0.73%，成交量4.26万手，成交额1.66亿元。 1月9日的资金流向数据方面，主力资金净流出268.42万元，占总成交额1.62%，游资资金净流出660.0万 元，占总成交额3.98%，散户资金净流入928.41万元，占总成交额5.59%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 稳健医疗2025年三季报显示，前三季度公司主营收入78.97亿元，同比上升30.1%；归母净利润7.32亿 元，同比上升32.36%；扣非净利润6.79亿元，同比上升43.93%；其中2025年第三季度，公司单季度主营 收入26.01亿元，同比上升27.71%；单季度归母净利润2.4亿元，同比上升42.11%；单季度扣非净利润 2.18亿元，同比上升50.77%；负债率33.87%，投资收益3323.27万元，财务费用-203.6万元，毛利率 48.32%。稳健医疗（30088 ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of the company Steady Medical (300888), including stock price movements and funding flows [1][2]. - As of January 7, 2026, Steady Medical's stock closed at 38.6 yuan, down 1.08%, with a trading volume of 47,000 hands and a transaction amount of 182 million yuan [1]. - In terms of funding flow on January 7, 2026, the main capital saw a net inflow of 6.1 million yuan, accounting for 3.35% of the total transaction amount, while retail investors experienced a net outflow of 123,700 yuan, representing 0.07% of the total [1]. Group 2 - For the first three quarters of 2025, Steady Medical reported a main revenue of 7.897 billion yuan, a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% [2]. - The third quarter of 2025 alone saw a main revenue of 2.601 billion yuan, reflecting a year-on-year growth of 27.71%, with a net profit of 240 million yuan, increasing by 42.11% [2]. - The company has a debt ratio of 33.87%, with investment income of 33.23 million yuan and a gross profit margin of 48.32% [2].

证券之星消息，截至2026年1月5日收盘，稳健医疗(300888)报收于39.34元，上涨3.96%，换手率 1.06%，成交量6.18万手，成交额2.4亿元。 1月5日的资金流向数据方面，主力资金净流出70.68万元，占总成交额0.3%，游资资金净流出1518.33万 元，占总成交额6.34%，散户资金净流入1589.01万元，占总成交额6.63%。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 稳健医疗2025年三季报显示，前三季度公司主营收 ...

证券之星消息，截至2025年12月23日收盘，稳健医疗(300888)报收于38.23元，下跌0.78%，换手率 0.35%，成交量2.03万手，成交额7761.43万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 12月23日的资金流向数据方面，主力资金净流入487.4万元，占总成交额6.28%，游资资金净流出824.48 万元，占总成交额10.62%，散户资金净流入337.09万元，占总成交额4.34%。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 稳健医疗2025年三季报显示，前三季度公司主营收入78.97亿元，同比上升30.1%；归母净利润7.32亿 元，同比上升32.36%；扣非净利润6.79亿元， ...

Group 1 - The core viewpoint of the news is that Steady Medical (300888) has shown significant growth in its financial performance for the first three quarters of 2025, with a notable increase in revenue and net profit compared to the previous year [2] - As of December 15, 2025, Steady Medical's stock closed at 37.43 yuan, down 1.03%, with a turnover rate of 0.43% and a trading volume of 24,800 hands, resulting in a transaction amount of 93.56 million yuan [1] - The company's main business includes the research, production, and sales of cotton products, covering medical health, personal care, family care, maternal and infant care, and home textiles [2] Group 2 - For the first three quarters of 2025, Steady Medical reported a main operating income of 7.897 billion yuan, a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% [2] - In the third quarter of 2025 alone, the company achieved a main operating income of 2.601 billion yuan, representing a year-on-year increase of 27.71%, and a net profit of 240 million yuan, up 42.11% [2] - The company has a debt ratio of 33.87%, with investment income of 33.23 million yuan and a gross profit margin of 48.32% [2]

Group 1 - The core viewpoint of the news is that Steady Medical (300888) has shown significant growth in its financial performance for the first three quarters of 2025, with a notable increase in revenue and net profit compared to the previous year [2] - As of December 10, 2025, Steady Medical's stock closed at 38.32 yuan, reflecting a 0.55% increase, with a trading volume of 23,800 lots and a total transaction amount of 90.74 million yuan [1] - The company's main business includes the research, production, and sales of cotton products, covering various sectors such as medical health, personal care, family care, maternal and infant care, and home textiles [2] Group 2 - For the first three quarters of 2025, Steady Medical reported a main revenue of 7.897 billion yuan, a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% [2] - In the third quarter of 2025 alone, the company achieved a main revenue of 2.601 billion yuan, representing a 27.71% year-on-year increase, and a net profit of 240 million yuan, which is a 42.11% increase compared to the same period last year [2] - The company has a debt ratio of 33.87% and a gross profit margin of 48.32%, indicating a stable financial position [2]

Core Insights - The company reported a significant increase in both revenue and profit for the first half of 2025, with revenue reaching 5.30 billion yuan, a year-on-year growth of 31.31% [1] - Net profit attributable to shareholders was 491.99 million yuan, reflecting a year-on-year increase of 28.07% [1] - The company’s basic earnings per share (EPS) rose to 0.84 yuan, up 28.64% compared to the previous year [1] Financial Performance - Revenue for the first half of 2025 was 5,296,211,956.92 yuan, compared to 4,033,505,104.33 yuan in the same period last year, marking a 31.31% increase [1] - Net profit attributable to shareholders was 491,998,009.07 yuan, up from 384,150,379.21 yuan, a growth of 28.07% [1] - The net profit after deducting non-recurring gains and losses was 460,623,731.26 yuan, which is a 40.90% increase from 326,915,114.82 yuan [1] - The net cash flow from operating activities was 339,925,774.07 yuan, a significant increase of 75.82% from 193,333,516.76 yuan [1] Profitability Metrics - The gross profit margin for the first half of 2025 was 48.33%, a decrease of 0.38 percentage points year-on-year [2] - The net profit margin was 9.78%, down 0.29 percentage points compared to the same period last year [2] Expense Analysis - Total operating expenses for the first half of 2025 amounted to 1.87 billion yuan, an increase of 403 million yuan from the previous year [2] - The expense ratio was 35.39%, which is a decrease of 1.08 percentage points year-on-year [2] - Sales expenses increased by 18.86%, management expenses rose by 40.95%, R&D expenses grew by 35.79%, and financial expenses surged by 69.73% [2] Leadership and Company Background - The chairman and general manager, Li Jianquan, received a salary of 2.947 million yuan in 2024, a slight decrease from 3.073 million yuan the previous year [4] - The company, established in August 2000 and listed in September 2020, specializes in the research, production, and sales of cotton products [4] - In 2024, the company reported an annual revenue of 8.978 billion yuan, a year-on-year increase of 9.69%, and a net profit of 695 million yuan, up 19.81% [4]

Group 1: Health Consumption Trends - The third China International Supply Chain Promotion Expo showcased various sectors, including a health living chain that attracted over 100 companies with new products and technologies [1] - There is a significant increase in health awareness among Chinese residents, leading to rapid growth in health consumption and an evolving consumer structure [1] - The market for cotton soft towels has surpassed 10 billion yuan, with the All Cotton Era brand leading in online sales [4][5] Group 2: Coffee and Personalized Health Solutions - A report indicates that 25% of young people in China consume at least one cup of coffee daily, with 36% of professionals stating they cannot work without it [2] - BGI launched a coffee metabolism gene test at the expo, allowing consumers to understand their sensitivity and metabolism of caffeine [2] - The trend towards personalized health management is growing, with home health devices making genetic testing more accessible [2] Group 3: Sports and Beverage Market Growth - The 2023 National Fitness Monitoring Report shows that 540 million people in China regularly exercise, with an average sports expenditure of 3,068 yuan per person [3] - The demand for sports drinks is rising, particularly for zero-calorie and low-sugar options, as consumer preferences evolve [3] - Tian Si Group introduced a bottled energy drink and a zero-sugar version of its classic product to cater to the growing health-conscious market [3] Group 4: Innovations in Health Products - All Cotton Era has transitioned medical innovations into consumer products, focusing on environmentally friendly and high-quality offerings [5][6] - The company has developed a cotton soft towel using a water-jet non-woven fabric process, significantly reducing production time and enhancing biodegradability [5] - Continuous investment in technology and innovation is aimed at meeting diverse consumer demands for health and quality [6]

Core Viewpoint - The company, Steady Medical, has shown strong performance in its consumer products and medical business segments, with significant growth in sales and profits, particularly during promotional events like the 618 shopping festival. Group 1: Consumer Products Performance - The consumer products segment performed well during the 618 shopping festival, with key categories such as facial towels, baby wet and dry wipes, and baby wraps ranking first in sales on platforms like Tmall and JD.com [2] - The company achieved notable sales growth in sanitary napkins and underwear, with traditional platforms like Tmall and JD.com showing good growth, while Douyin saw breakthrough growth during the event [2] - The company is confident in achieving its equity incentive goals for the year [2] Group 2: E-commerce Strategy - Online channels contribute over 60% to the overall revenue of the consumer products business, making it a primary source of profit [3] - The company covers a wide range of online platforms, including traditional e-commerce sites and interest-based platforms like Douyin and Xiaohongshu, as well as its own website and mini-programs [3] - Future strategies include focusing on strategic product development on traditional platforms and leveraging interest-based platforms for content dissemination to drive growth [3] Group 3: Adult Apparel Business Changes - The adult apparel segment has undergone changes to enhance market competitiveness, focusing on underwear and loungewear [4] - The company has strengthened its core fabric research and innovation, emphasizing comfort and health in its cotton products [4] - A high-profile endorsement from actress Zhao Liying has been utilized to boost brand awareness, with interactive marketing strategies during the 618 festival [4] Group 4: Membership Growth - As of the end of Q1 2025, the total membership across all channels exceeded 64 million, reflecting a 3.5% increase since the beginning of the year [5] - The company aims to enhance member engagement and loyalty through improved services and participation in brand activities [5] - A themed event focusing on comfort and environmental sustainability was held to engage young consumers [5] Group 5: Medical Business Development - The medical business strategy focuses on developing high-potential products like high-end dressings and surgical kits while nurturing emerging categories such as masks and disinfectants [6] - The company anticipates continued growth in high-end dressings and surgical supplies, with stable growth expected in traditional wound dressings [6] - The demand for infection prevention products is expected to normalize, providing stable revenue contributions [6] Group 6: Domestic Hospital Business Strategy - The domestic hospital business is expected to achieve good growth in 2025, focusing on traditional wound care, surgical supplies, and high-end dressings [7] - The company plans to leverage procurement opportunities to increase market share in traditional wound care [7] - Efforts are being made to promote non-standardized products and expand market opportunities in surgical supplies [7] Group 7: Financial Performance - For Q1 2025, the company reported a main revenue of 2.605 billion yuan, a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also up 36.26% [8] - The company’s gross profit margin stands at 48.46%, indicating strong profitability [8] - Recent institutional ratings show 19 buy ratings and 3 hold ratings, with an average target price of 57.07 yuan [8]